Limitations of a TCP model incorporating population heterogeneity

Physics in Medicine and Biology

Volumn 50, Issue 15, 2005, Pages 3571-3588

  Warkentin, B ^a,b   Stavrev, P ^a   Stavreva, N A ^a   Fallone, B G ^a,b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC RADIOGRAPHY; DRUG DOSAGE; FRACTIONATION; MONTE CARLO METHODS; PROBABILITY; RADIOTHERAPY;

CLINICAL DOSE-RESPONSE DATA; POPULATION HETEROGENEITY; RADIOBIOLOGICAL PARAMETERS; TUMOR CONTROL PROBABILITY (TCP);

TUMORS;

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; MATHEMATICAL ANALYSIS; MONTE CARLO METHOD; POISSON DISTRIBUTION; POPULATION MODEL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIVITY;

ANIMALS; APOPTOSIS; CELL SURVIVAL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 22544439961     PISSN: 00319155     EISSN: None     Source Type: Journal    
DOI: 10.1088/0031-9155/50/15/006     Document Type: Article

References (56)

1. Alsbeih G, Malone S, Lochrin C, Girard A, Fertil B and Raaphorst G P 2000 Correlation between normal tissue complications and in vitro radiosensitivity of skin fibroblasts derived from radiotherapy patients treated for variety of tumors Int. J. Radiat. Oncol. Biol. Phys. 46 143-52
2. Bentzen S M 1992 Steepness of the clinical dose-control curve and variation in the in vitro radiosensitivity of head and neck squamous-cell carcinoma Int. J. Radiat. Biol. 61 417-23
3. Bentzen S M and Tucker S L 1998 Individualization of radiotherapy dose prescriptions by means of an in vitro radiosensitivity assay Radiother. Oncol. 46 216-8
4. Brenner D J and Hall E J 1999 Fractionation and protraction for radiotherapy of prostate carcinoma Int. J. Radiat. Oncol. Biol. Phys. 43 1095-101
5. Brenner D J, Martinez A A, Edmundson G K, Mitchell C, Thames H D and Armour E P 2002 Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int. J. Radiat. Oncol. Biol. Phys. 52 6-13
6. Brock W A, Tucker S L, Geara F B, Turesson I, Wike J, Nyman J and Peters L J 1995 Fibroblast radiosensitivity versus acute and late normal skin-responses in patients treated for breast-cancer Int. J. Radiat. Oncol. Biol. Phys. 32 1371-9
7. Budach W, Classen J, Belka C and Bamberg M 1998 Clinical impact of predictive assays for acute and late radiation morbidity Strahlenther. Onkol. 174 20-4
8. Buffa F M, Davidson S E, Hunter R D, Nahum A E and West C M L 2001 Incorporating biologic measurements (SF2, CFE) into a tumor control probability model increases their prognostic significance: a study in cervical carcinoma treated with radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 50 1113-22
9. Buffa F M, Fenwick J D and Nahum A E 1999 Concerning Roberts and Hendry IJROBP 1998; 41:689-699 Int. J. Radiat. Oncol. Biol. Phys. 44 737-9
10. Carlone M, Wilkins D, Nyiri B and Raaphorst P 2003 Comparison of alpha/beta estimates from homogeneous (individual) and heterogeneous (population) tumor control models for early stage prostate cancer Med. Phys. 30 2832-48
11. Carlone M, Wilkins D, Nyiri B and Raaphorst P 2004 TCP isoeffect analysis using a heterogeneous distribution of radiosensitivity Med. Phys. 31 1176-82
12. Chappell R, Fowler J F and Ritter M A 2002 Is the alpha/beta for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021-1031 - in response to Drs. Dale and Jones Int. J. Radiat. Oncol. Biol. Phys. 52 1428
13. Collett D 1991 Modelling Binary Data (New York: Chapman and Hall)
14. Dale R G 1989a Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model Br. J. Radiol. 62 241-4
15. Dale R G 1989b Time-dependent tumor repopulation factors in linear-quadratic equations - implications for treatment strategies Radiother. Oncol. 15 371-82
16. Dikomey E, Borgmann K, Peacock J and Jung H 2003 Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed Int. J. Radiat. Oncol. Biol. Phys. 56 1194-200
17. Dubray B M and Thames H D 1996 The clinical significance of ratios of radiobiological parameters Int. J. Radiat. Oncol. Biol. Phys. 35 1099-111
18. Fenwick J D 1998 Predicting the radiation control probability of heterogeneous tumour ensembles: data analysis and parameter estimation using a closed-form expression Phys. Med. Biol. 43 2159-78
19. Fischer J J and Moulder J E 1975 Steepness of dose-response curve in radiation-therapy - theoretical considerations and experimental results Radiology 117 179-84
20. Fowler J F 1989 The linear-quadratic formula and progress in fractionated radiotherapy Br. J. Radiol. 62 679-94
21. Fowler J, Chappell R and Ritter M 2001 Is alpha/beta for prostate tumors really low? Int. J. Radiat. Oncol. Biol. Phys. 50 1021-31
22. Girinsky T et al 1994 In vitro parameters and treatment outcome in head and neck cancers treated with surgery and/or radiation - cell characterization and correlations with local-control and overall survival Int. J. Radiat. Oncol. Biol. Phys. 30 789-94
23. Goitein M, Niemierko A and Okunieff P 1995 The probability of controlling an inhomogeneously irradiated tumour: a stratagem for improving tumour control through partial tumour boosting Proc. 19th L H Gray Conf.: Quantitative Imaging in Oncology (Newcastle, UK) pp 25-39
24. Haikonen J, Rantanen V, Pekkola K, Kulmala J and Grenman R 2003 Does skin fibroblast radiosensitivity predict squamous cancer cell radiosensitivity of the same individual? Int. J. Cancer 103 784-8
25. Kal H B, Van and Gellekom M P R 2003 How low is the alpha/beta ratio for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 57 1116-21
26. King C R and Mayo C S 2000 Is the prostrate alpha/beta ratio of 1.5 from Brenner & Hall a modeling artifact Int. J. Radiat. Oncol. Biol. Phys. 47 536-9
27. Maciejewski B, Withers H R, Taylor J M G and Hliniak A 1989 Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx - tumor dose-response and repopulation Int. J. Radiat. Oncol. Biol. Phys. 16 831-43
28. Maciejewski B, Withers H R, Taylor J M G and Hliniak A 1990 Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: 2. Normal tissue responses - acute and late effects Int. J. Radiat. Oncol. Biol. Phys. 18 101-11
29. Mackay R I and Hendry J H 1999 The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability Radiother. Oncol. 50 67-75
30. Oppitz U, Baier K, Wulf J, Schakowski R and Flentje M 2001 The in vitro colony assay: a predictor of clinical outcome Int. J. Radiat. Biol. 77 105-10
31. Press W H, Flannery B P, Teukolsky S A and Vetterling W T 1986 Numerical Recipes (Cambridge: Cambridge University Press)
32. Roberts S A and Hendry J H 1993 The delay before onset of accelerated tumour cell repopulation during radiotherapy: a direct maximum-likelihood analysis of a collection of worldwide tumour-control data Radiother. Oncol. 29 69-74
33. Roberts S A and Hendry J H 1998 A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity Int. J. Radiat. Oncol. Biol. Phys. 41 689-99
34. Rudat V, Dietz A, Nollert J, Conradt C, Weber K J, Flentje M and Wannenmacher M 1999 Acute and late toxicity, tumour control and intrinsic radiosensitivity of primary fibroblasts in vitro of patients with advanced head and neck cancer after concomitant boost radiochemotherapy Radiother. Oncol. 53 233-45
35. Sanchez-Nieto B, Nahum A E and Dearnaley D P 2001 Individualization of dose prescription based on normal-tissue dose-volume and radiosensitivity data Int. J. Radiat. Oncol. Biol. Phys. 49 487-99
36. Slonina D, Klimek M, Szpytma K and Gasinska A 2000 Comparison of the radiosensitivity of normal-tissue cells with normal-tissue reactions after radiotherapy Int. J. Radiat. Biol. 76 1255-64
37. Stausbol-Gron B, Bentzen S M, Jorgensen K E, Nielsen O S, Bundgaard T and Overgaard J 1999 In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data Br. J. Cancer 79 1074-84
38. Stavrev P, Niemierko A, Stavreva N and Goitein M 2001a The application of biological models to clinical data Phys. Med. 17 71-82
39. Stavrev P, Stavreva N, Niemierko A and Goitein M 2001b Generalization of a model of tissue response to radiation based on the idea of functional subunits and binomial statistics Phys. Med. Biol. 46 1501-18
40. Stavrev P, Warkentin B, Stavreva N and Fallone G 2002 Evaluation of a closed-form tumor control probability solution Med. Phys. 29 1294
41. Suit H, Skates S, Taghian A, Okunieff P and Efird J T 1992 Clinical Implications of Heterogeneity of tumor response to radiation-therapy Radiother. Oncol. 25 251-60
42. Taylor J M G, Withers H R and Mendenhall W M 1990 Dose-time considerations of head and neck squamous-cell carcinomas treated with irradiation Radiother. Oncol. 17 95-102
43. Thames H D, Bentzen S M, Turesson I, Overgaard M and Vandenbogaert W 1990 Time-dose factors in radiotherapy - a review of the human data Radiother. Oncol. 19 219-35
44. Travis E L and Tucker S L 1987 Isoeffect models and fractionated radiation-therapy Int. J. Radiat. Oncol. Biol. Phys. 13 283-7
45. Tucker S L and Travis E L 1990 Comments on a time-dependent version of the linear-quadratic model Radiother. Oncol. 18 155-63
46. Vandegeijn J 1989 Incorporating the time factor into the linear-quadratic model Br. J. Radiol. 62 296-8
47. Van Dyk J, Mah K and Keane T J 1989 Radiation-induced lung damage - dose-time-fractionation considerations Radiother. Oncol. 14 55-69
48. Wang J Z, Guerrero M and Li X A 2003a How low is the alpha/beta ratio for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 55 194-203
49. Wang J Z, Li X A, Yu C X and DiBiase S J 2003b The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int. J. Radiat. Oncol. Biol. Phys. 57 1101-8
50. Wang J Z, Mayr N A, Li X A and Stewart R D 2005 Modeling prostate cancer: in regards to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401) Int. J. Radiat. Oncol. Biol. Phys. 61 309-10
51. Webb S 1994 Optimum parameters in a model for tumor-control probability including interpatient heterogeneity Phys. Med. Biol. 39 1895-914
52. West C M L et al 1998 The intrinsic radiosensitivity of normal and tumour cells Int. J. Radiat. Biol. 73 409-13
53. Wheldon T E and Amin A E 1988 The linear quadratic model Br. J. Radiol. 61 700-2
54. Withers H R, Taylor J M G and Maciejewski B 1988 The hazard of accelerated tumor clonogen repopulation during radiotherapy Acta Oncol. 27 131-46
55. Yaes R J 1989 Linear-quadratic model isoeffect relations for proliferating tumor-cells for treatment with multiple fractions per day Int. J. Radiat. Oncol. Biol. Phys. 17 901-5
56. Zagars G K, Schultheiss T E and Peters L J 1987 Inter-tumor heterogeneity and radiation dose-control curves Radiother. Oncol. 8 353-62